Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

被引:16
|
作者
Zhou, Hong [1 ,2 ,3 ]
Ma, Yipeng [2 ,3 ]
Liu, Fenglan [2 ,3 ]
Li, Bin [2 ,3 ]
Qiao, Dongjuan [2 ,3 ]
Ren, Peigen [1 ]
Wang, Mingjun [2 ,3 ]
机构
[1] Chinese Acad Sci, Ctr Energy Metab & Reprod, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China
[2] Shenzhen Innovat Immunotechnol Co Ltd, Dept Res & Dev, Shenzhen, Peoples R China
[3] Shenzhen Inst Innovat & Translat Med, Dept Res & Dev, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
CTA; NY-ESO-1; cancer vaccine; immunotherapy; solid cancer; T-CELL RESPONSES; NY-ESO-1-SPECIFIC IMMUNE-RESPONSES; TESTIS ANTIGEN NY-ESO-1; MESSENGER-RNA; OVARIAN-CANCER; POLY-ICLC; EXPRESSING NY-ESO-1; MELANOMA PATIENTS; DENDRITIC CELLS; VACCINATION;
D O I
10.3389/fimmu.2023.1255799
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4+ T cells via major histocompatibility complex class II (MHC-II) and to CD8+ T cells via major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] NY-ESO-1 protein expression and humoral immune responses in prostate cancer
    Fosså, A
    Berner, A
    Fosså, SD
    Hernes, E
    Gaudernack, G
    Smeland, EB
    PROSTATE, 2004, 59 (04): : 440 - 447
  • [32] NY-ESO-1 protein cancer vaccine with TLR 3 and 4 agonists
    Takeoka, Tomohira
    Nagase, Hirotsugu
    Miyazaki, Yasuhiro
    Takahashi, Tsuyoshi
    Kurokawa, Yukinori
    Makino, Tomoki
    Yamasaki, Makoto
    Takiguchi, Shuji
    Mori, Masaki
    Doki, Yuichiro
    Wada, Hisashi
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [33] WT1, NY-ESO-1 AND PRAME EXPRESSION IN BREAST CANCER SUBTYPES
    Esposito, A.
    Bagnardi, V.
    Criscitiello, C.
    Gelao, L.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2014, 25 : 18 - 18
  • [34] Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
    Al-Marayaty, Rusul
    Pollack, Seth M.
    CELL REPORTS MEDICINE, 2023, 4 (08)
  • [35] Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
    Afsheen Raza
    Maysaloun Merhi
    Varghese Philipose Inchakalody
    Roopesh Krishnankutty
    Allan Relecom
    Shahab Uddin
    Said Dermime
    Journal of Translational Medicine, 18
  • [36] Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
    Raza, Afsheen
    Merhi, Maysaloun
    Inchakalody, Varghese Philipose
    Krishnankutty, Roopesh
    Relecom, Allan
    Uddin, Shahab
    Dermime, Said
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [37] NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
    Ademuyiwa, Foluso O.
    Bshara, Wiam
    Attwood, Kristopher
    Morrison, Carl
    Edge, Stephen B.
    Ambrosone, Christine B.
    O'Connor, Tracey L.
    Levine, Ellis G.
    Miliotto, Anthony
    Ritter, Erika
    Ritter, Gerd
    Gnjatic, Sacha
    Odunsi, Kunle
    PLOS ONE, 2012, 7 (06):
  • [38] B-cell epitopes from the cancer testis antigen NY-ESO-1
    Preuss, KD
    Regitz, E
    Neumann, F
    Pfreundschuh, M
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (01) : 253 - 253
  • [40] The Role of NY-ESO-1 Activated Dendritic Cell Vaccines in Treating Advanced Non-small Cell Lung Cancer
    Dan, Yu
    Tang, Jianli
    Li, Qiasheng
    Zhang, Huanhuan
    Zhou, Chengzhi
    Zheng, Runhui
    Xu, Jun
    CHEST, 2016, 149 (04) : 313A - 313A